This inventor holds 3 USPTO granted patents and 3 published patent applications and 1 EPO patent. Top assignee: Actelion Pharmaceuticals Ltd. Active years: 2022-2023.
Location History:
- Bubendorf, CH (2022)
- Allschwil, CH (2023)
Company Filing History:
Years Active: 2022-2023
Title: Hans Hoogkamer: Innovator in Pharmaceutical Composition
Introduction
Hans Hoogkamer is a notable inventor based in Bubendorf, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of pulmonary hypertension. With a total of 3 patents to his name, Hoogkamer's work is recognized for its innovative approaches to medical treatment.
Latest Patents
Hoogkamer's latest patents include a pharmaceutical composition comprising macitentan for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH). This invention focuses on high doses of macitentan and its use in the treatment and prevention of CTEPH. Additionally, he has developed a pharmaceutical composition for the treatment of pulmonary arterial hypertension (PAH), which also utilizes high doses of macitentan or aprocitentan. Both inventions emphasize the importance of dosage regimens and combinations with other therapeutic agents to enhance treatment efficacy.
Career Highlights
Hans Hoogkamer is associated with Actelion Pharmaceuticals Ltd., where he has been instrumental in advancing pharmaceutical research and development. His work has contributed to the understanding and treatment of complex pulmonary conditions, showcasing his expertise in the field.
Collaborations
Hoogkamer has collaborated with notable colleagues such as Wassim Fares and Koen Torfs, further enhancing the impact of his research and innovations in the pharmaceutical industry.
Conclusion
Hans Hoogkamer's contributions to pharmaceutical compositions demonstrate his commitment to improving treatment options for patients with pulmonary hypertension. His innovative patents reflect a deep understanding of medical needs and the potential for new therapies.